How much funding has Verve Therapeutics raised?

Verve Therapeutics has raised $428.5M in total funding, most recently a Series C round.

Who are Verve Therapeutics's investors?

Verve Therapeutics's investors include GV, Foresite Capital, ARCH Venture Partners, F-Prime Capital, Redmile Group, Janus Henderson Investors.

When was Verve Therapeutics founded?

Verve Therapeutics was founded in 2018.

Where is Verve Therapeutics headquartered?

Verve Therapeutics is headquartered in Boston, Massachusetts, United States.

What industry is Verve Therapeutics in?

Verve Therapeutics operates in Biotech, Drug Discovery, Genomics, Healthcare, Therapeutics.

How many employees does Verve Therapeutics have?

Verve Therapeutics has 201-500 employees.

Verve Therapeutics

Acquired

We are on a mission to protect the world from cardiovascular disease

Boston, United States · Founded 2018 · $428.5M raised

Headquarters: Boston, Massachusetts
Employees: 201–500
Founded: 2018
Business Model: B2B

Website: vervetx.com
Total Funding: $428.5M
Last Round: $213.0M Series COct 2024
Rounds: 4

About

Verve Therapeutics is a clinical-stage company developing single-course, in vivo gene editing medicines to permanently lower cardiovascular disease risk. Its platform uses base editing to precisely inactivate genes in the liver — such as PCSK9 and ANGPTL3 — that contribute to atherosclerotic cardiovascular disease. Lead programs VERVE-101 and VERVE-102 are advancing through Phase 1b clinical trials with FDA Fast Track Designation.

Summary

Verve Therapeutics is a Biotech company based in Boston, United States, founded in 2018. It has raised $428.5M in total across 4 rounds, most recently a $213.0M Series C round in Oct 2024. Investors include GV, Foresite Capital and ARCH Venture Partners.

LinkedIn X (Twitter)